

T M, Bogenmann E, Ponzoni M. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. *Int J Cancer*. 2003; 104:559-67.

106. Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase E H, Allen T M, Ponzoni M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. *Cancer Res*. 2003; 63:86-92.

107. Burbridge M F, Kraus-Berthier L, Naze M, Pierre A, Atassi G, Guilbaud N. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity. *Int J Oncol*. 1999; 15:1155-62.

108. Liao C P, Zhong C, Saribekyan G, Bading J, Park R, Conti P S, Moats R, Berns A, Shi W, Zhou Z, Nikitin A Y, Roy-Burman P. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. *Cancer Res*. 2007; 67:7525-33.

The contents of all references cited herein are incorporated by reference in their entirety.

What is claimed is:

1. A method of contacting a prostate cancer cell with a chemotherapy agent, comprising:

starving the prostate cancer cell for 24-60 hours to induce differential stress by cultivating the prostate cancer cell in a medium having a glucose level reduced by 25 to 45 percent compared to normal glucose levels for the prostate cancer cell and a reduced IGF-I level compared to normal IGF-I levels for the prostate cancer cell; and contacting the prostate cancer cell with the chemotherapy agent.

2. The method of claim 1, further comprising contacting the cancer cell with a cell growth inhibitor of IGFBP-1.

\* \* \* \* \*